Company Encyclopedia
View More
name
MiNK Therapeutics
INKT.US
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc.
1.935 T
INKT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MiNK Therapeutics | 8-K: FY2025 Q3 EPS Beats Estimate at USD -0.65

    LB filings·
    US
    INKT
    +0.60%
    LB filings·
    US
    INKT
    +0.60%

    MiNK Therapeutics Reports MiNK-215 Shows Strong Anti-Tumor Activity in Resistant Solid Tumors

    MiNK Therapeutics Inc. has announced promising preclinical results for MiNK-215, a novel therapy targeting resistant solid tumors. Published in Cancer Immunology Research, MiNK-215, an IL-15-enhanced, FAP-targeting CAR-iNKT cell therapy, shows strong anti-tumor activity by dismantling tumor-protective barriers and activating immune pathways. It offers a scalable, off-the-shelf treatment option for patients unresponsive to conventional therapies. The original content was published by MiNK Therapeutics via GlobeNewswire on November 20, 2025.

    Reuters·
    US
    INKT
    +0.60%
    Reuters·
    US
    INKT
    +0.60%

    MiNK Therapeutics (NASDAQ:INKT) Posts Earnings Results, Beats Expectations By $0.21 EPS

    MiNK Therapeutics reported quarterly earnings with an EPS of ($0.65), beating the consensus estimate of ($0.86) by $0.21. Despite this, shares fell $0.47 to $12.75. Analysts have mixed ratings, ranging from "strong sell" to "strong buy," with a consensus of "Moderate Buy" and a target price of $37.50. The company focuses on iNKT cell therapies for cancer and immune diseases, with its product AGENT-797 in Phase 1 trials.

    Market Beat·
    US
    INKT
    +0.60%
    Market Beat·
    US
    INKT
    +0.60%

    MiNK Therapeutics Earnings Call: Positive Sentiment and Promising Future

    MiNK Therapeutics' Q3 earnings call highlighted positive sentiment due to successful clinical trials, strategic partnerships, and enhanced manufacturing capabilities. Despite a net loss increase to $2.9 million, the company maintains a stable cash balance and plans for future growth. Key leadership appointments and public-private partnerships support ongoing research and development, indicating a promising future for its innovative therapies.

    Tip Ranks·
    US
    INKT
    +0.60%
    Tip Ranks·
    US
    INKT
    +0.60%

    MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary Diseases

    Emily Bodnar from H.C. Wainwright maintains a Buy rating on MiNK Therapeutics with a $35 target, citing advancements in clinical trials and strategic partnerships. MiNK is initiating a Phase 2 trial for agenT-797 targeting GvHD, supported by grants and collaborations, and a Phase 2+ trial for severe pulmonary diseases, aiming for FDA approval. These efforts highlight MiNK's strategic focus on expanding its therapeutic pipeline and market position.

    Tip Ranks·
    US
    INKT
    +0.60%
    Tip Ranks·
    US
    INKT
    +0.60%
    © 2025 Longbridge｜Disclaimer